After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...
Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...
CDMO Joinn Biologics snaps up China biologics plant from Lonza in push to tackle Asia-Pacific market
With the purchase of a former Lonza biologics plant now in the books, San Francisco-based CDMO Joinn Biologics is expanding from one Bay Area to another. | CDMO Joinn Biologics has completed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback